Journal of Thoracic Oncology (JTO), January 2021, Volume 16, Issue 1
Journal | English | 2021
Image For Activity Cover
Credit Offered
No Credit Offered
In This Issue
  • From the IASLC Tobacco Control Committee
  • One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
  • Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma
  • Lung Cancer Stigma Then and Now: Continued Challenges Amid a Landscape of Progress
Editorial - Lung Cancer Worldwide
  • Lung Cancer in France
Statistics in Oncology Series
  • Principles and Reporting of Bayesian Trials
State of the Art: Concise Review
  • Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation
Special Articles
  • American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC
  • American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020
Original Articles
  • The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data
  • UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma
  • HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival
  • Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers
  • Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC
  • Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
Brief Reports
  • A 10-Year Cross-Sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated Stigma
  • Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALKD NSCLC
  • Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
Case Reports
  • Identification and Resolution of Asymptomatic COVID-19 Pneumonitis and Colitis: Serial Assessment of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Evaluation of Lung Cancer
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By